Please assess the completion status of the following clinical trial:

Trial Title: Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed NODAT defined by pathologic OGTT (2h, 75mg glucose):~glucose ≥ 200mg/dl~* Defect in insulin secretion as judged by OGTT and HOMA B~* Renal transplantation (deceased or living donor) and treatment with the standard immunosuppression at our center, consisting of tacrolimus, mycophenolate mofetil, prednisone triple therapy without any induction~* stable graft function for more than 3 months post transplant~* informed consent of the patient~Exclusion Criteria:~* patients with prior history of type 1 or type 2 diabetes~* time since transplantation more than 20 years~* allergy against long-acting insulin or cyclosporine A~* body mass index (BMI) \> 35~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporine A (Type: EXPERIMENTAL): Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
- Tacrolimus (Type: ACTIVE_COMPARATOR): Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.

Based on this trial design, predict the completion outcome and termination type (if applicable).